Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
The Gabelli ABC Fund Mario J. Gabelli, CFA, Willis Brucker | “SpringWorks Therapeutics Inc. (3.6%) (SWTX – $46.99 – NASDAQ) is a commercial stage biotech focused on the treatment of various forms of cancer and rare diseases. After several months of press speculation, German based Merck KGaA inked an agreement to acquire SWTX for $47 cash per share on April 28. The deal remains subject to final approval by shareholders and is expected to close early in the third quarter. BSD Analysis: SpringWorks Therapeutics is a high-growth, specialized biotech pure-play whose stock is a conviction bet on the successful commercialization of its oncology pipeline, anchored by Ogsiveo. The core thesis is driven by Ogsiveo's (nirogacestat) recent FDA approval for desmoid tumors, a rare cancer, which provides a near-monopoly in a high-value niche. The company is strategically positioned to capture market share with this differentiated asset. The stock is a leveraged play on the successful launch execution of Ogsiveo and the advancement of its deep pipeline of γ−secretase inhibitors and other precision oncology assets.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
